U.S. markets close in 2 hours 43 minutes
  • S&P 500

    4,448.42
    -34.31 (-0.77%)
     
  • Dow 30

    34,575.54
    -139.85 (-0.40%)
     
  • Nasdaq

    13,990.14
    -163.88 (-1.16%)
     
  • Russell 2000

    2,013.42
    -10.61 (-0.52%)
     
  • Crude Oil

    84.73
    -0.82 (-0.96%)
     
  • Gold

    1,832.10
    -10.50 (-0.57%)
     
  • Silver

    24.30
    -0.42 (-1.70%)
     
  • EUR/USD

    1.1348
    +0.0031 (+0.27%)
     
  • 10-Yr Bond

    1.7530
    -0.0800 (-4.36%)
     
  • GBP/USD

    1.3564
    -0.0036 (-0.27%)
     
  • USD/JPY

    113.6850
    -0.4150 (-0.36%)
     
  • BTC-USD

    38,597.63
    -4,437.41 (-10.31%)
     
  • CMC Crypto 200

    907.21
    +664.53 (+273.83%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.67 (-0.90%)
     

Mersana Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • MRSN
  • STOK

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Company’s management team will participate in a fireside chat on Wednesday, February 24, 2021 at 10:00 a.m. ET at the SVB Leerink 10th Annual Global Healthcare Conference.

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90-days following the presentation.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (XMT-1536, UpRi), is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:
Investor & Media Contact
Sarah Carmody
617-844-8577
scarmody@mersana.com